MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH;ACORDA THERAPEUTICS, INC.
发明人:
GRUSKIN, ELLIOT A.,CHOJNICKI, ERIC,WARRINGTON, ARTHUR E.,BIEBER, ALLAN J.,RODRIGUEZ, MOSES
申请号：
CA2525917
公开号：
CA2525917C
申请日:
2004.05.17
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
Antibodies, and particularly human antibodies, are disclosed that demonstrateactivity in the treatment of demyelinating diseases as well as other diseasesof the central nervous system that are of viral, bacterial or idiopathicorigin, including neural dysfunction caused by spinal cord injury.Neuromodulatory agents are set forth that include and comprise a materialselected from the group consisting of an antibody capable of bindingstructures or cells in the central nervous system, a peptide analog, a hapten,active fragments thereof, agonists thereof, mimics thereof, monomers thereofand combinations thereof. Methods are described for treating demyelinatingdiseases, and diseases of the central nervous system of humans and domesticanimais, using polyclonal IgM antibodies and human monoclonal antibodiessHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12,CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. Theinvention also extends to the use of human antibodies, fragments, peptidederivatives and like materials, and their use in above referenced therapeuticapplications, and to pharmaceutical compositions containing them, that may beadministered in desirably low doses to treat conditions involvingdemyelination and to promote remyelination.
